Union Bancaire Privee UBP SA Takes Position in Edwards Lifesciences Co. (NYSE:EW)

Union Bancaire Privee UBP SA acquired a new position in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, Holdings Channel reports. The firm acquired 14,802 shares of the medical research company’s stock, valued at approximately $1,120,000.

Several other institutional investors and hedge funds have also recently modified their holdings of EW. Wellington Management Group LLP grew its stake in Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after buying an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Edwards Lifesciences by 239.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after acquiring an additional 2,606,950 shares in the last quarter. Seilern Investment Management Ltd purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $109,490,000. Finally, Nordea Investment Management AB boosted its stake in Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after acquiring an additional 1,043,484 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock worth $2,195,180 in the last three months. Corporate insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on EW. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price for the company. in a report on Thursday, January 16th. Morgan Stanley reiterated an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Evercore ISI lowered their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Stock Up 0.3 %

Shares of EW stock opened at $69.21 on Tuesday. The company has a 50 day simple moving average of $72.33 and a two-hundred day simple moving average of $70.36. The stock has a market cap of $40.82 billion, a P/E ratio of 9.99, a P/E/G ratio of 3.54 and a beta of 1.11. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.